Effects of selective serotonin reuptake inhibitors on bone health in adults: Time for recommendations about screening, prevention and management?

Bone

Volumn 46, Issue 1, 2010, Pages 13-17

  Haney, Elizabeth M ^a   Warden, Stuart J ^b,c   Bliziotes, M Michael ^a,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Bone; Depression; Epidemiology; Neurotransmitter; Screening; Selective serotonin reuptake inhibitor; Serotonin

Indexed keywords

SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; BODY MASS; BONE DENSITY; BONE DISEASE; BONE METABOLISM; CAUSAL ATTRIBUTION; CHRONIC PAIN; CLINICAL RESEARCH; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FALLING; FAMILY HISTORY; FIBROMYALGIA; FRACTURE; GENERALIZED ANXIETY DISORDER; GENETIC DIFFERENCE; HUMAN; LIFESTYLE; MAJOR DEPRESSION; MENOPAUSAL SYNDROME; OSSIFICATION; OSTEOLYSIS; PANIC; PHYSICAL ACTIVITY; POSTTRAUMATIC STRESS DISORDER; PREMENSTRUAL DYSPHORIC DISORDER; RECURRENCE RISK; REVIEW; RISK FACTOR; RISK MANAGEMENT; SCREENING; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

ADULT; ANTIDEPRESSIVE AGENTS; BONE AND BONES; BONE DENSITY; DEPRESSION; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 72049128309     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.07.083     Document Type: Review

References (67)

1. Bliziotes M., et al. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone 29 5 (2001) 477-486
2. Westbroek I., et al. Expression of serotonin receptors in bone. J. Biol. Chem. 276 31 (2001) 28961-28968
3. Yadav V.K., et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135 5 (2008) 825-837
4. Rosen C.J. Serotonin Rising-The Bone, Brain, Bowel Connection. N Engl J Med 360 10 (2009) 957-959
5. C.J. Rosen, Breaking into bone biology: serotonin's secrets. 2009. 15(2): 145-146.
6. Long F. When the gut talks to bone. Cell 135 (2008) 795-796
7. Warden S.J., et al. The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5). Bone 46 (2010) 4-12
8. Haney E.M., et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch. Intern. Med. 167 12 (2007) 1246-1251
9. Richards J.B., et al. The impact of selective serotonin reuptake inhibitors on the risk of fracture. Arch. Intern. Med. 167 2 (2007) 188-194
10. Williams L.J., et al. Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int. Clin. Pscyhopharmacol. 23 (2008) 84-87
11. Diem S., et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch. Intern. Med. 167 12 (2007) 1240-1245
12. Kinjo M., et al. Bone mineral density in subjects using central nervous system-active medications. Am. J. Med. 118 12 (2005) 1414.e7-1414.e12
13. Spangler L., et al. Depressive symptoms, bone loss, and fractures in postmenopausal women. J. Gen. Intern. Med. (2008 Feb 20) (electronic publication ahead of print; COI 10.1007/x11606-008-0525-0)
14. Vestergaard P., Rejnmark L., and Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos. Int. 17 (2006) 807
15. Bolton J.M., et al. Fracture risk from psychotropic medications: a population-based analysis. J. Clin. Psychopharmacol. 28 4 (2008) 384-391
16. Ray W.A., et al. Psychotropic drug use and the risk of hip fracture. N. Engl. J. Med. 316 7 (1987) 363-369
17. Liu B., et al. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 351 (1998) 1303-1307
18. Richelson E. Pharmacology of antidepressants. May Clin. Proc. 76 (2001) 511-527
19. Haney E.M., et al. SSRI use is associated with increased risk of fracture among older men. JBMR 22 Suppl. 1 (2007) s45
20. Lewis C.E., et al. Predictors of non-spine fracture in elderly men: the MrOS study. J. Bone Miner. Res. 22 2 (2007) 211-219
21. Ensrud K.E., et al. Central nervous system active medications and risk for fractures in older women. Arch. Intern. Med. 163 (2003) 949-957
22. Hulley S.B., et al. Designing clinical research. 2nd Ed. (2001), Lippincott Williams and Wilkins, Philadelphia, PA
23. Ziere G., et al. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J. Clin. Psychopharmacol. 28 (2008) 411-417
24. Hubbard R., et al. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am. J. Epidemiol. 158 1 (2003) 77-84
25. Bliziotes M.M., et al. Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells. Bone 39 6 (2006) 1313-1321
26. Warden S.J., et al. Neural regulation of bone and the skeletal effects of serotonin (5-hydroxytryptamine). Mol. Cell. Endocrinol. 242 1-2 (2005) 1-9
27. Warden S.J., et al. Serotonin (5-hydroxytryptamine) transporter inhibition causes bone loss in adult mice independently of estrogen deficiency. Menopause 15 6 (2008) 1176-1183
28. Battaglino R., et al. Serotonin regulates osteoclast differentiation through its transporter. J. Bone Miner. Res. 19 9 (2004) 1420-1431
29. Psaty B., et al. Assessment and control for confounding by indication in observational studies. J. Am. Geriatr. Soc. 47 6 (1997) 749-754
30. Coelho R., et al. Bone mineral density and depression: a community study in women. J Psychosom. Res. 46 1 (1999) 29-35
31. Diem S.J., et al. Depressive symptoms and rates of bone loss at the hip in older women. J Am. Geriatr. Soc. 55 (2007) 824-831
32. Robbins J., et al. The association of bone mineral density and depression in an older population. J. Am. Geriatr. Soc. 49 (2001) 732-736
33. Silverman S.L., et al. Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. J. Rheumatol. 34 1 (2007) 140-144
34. Mussolino M.E., Jonas B.S., and Looker A.C. Depression and bone mineral density in young adults: results from NHANES III. Psychosom. Med. 66 (2004) 533-537
35. Wong S.Y.S., et al. Depression and bone mineral density: is there a relationship in elderly Asian men? Results from Mr. Os (Hong Kong). Osteoporos. Int. 16 (2005) 610-615
36. Jacka F.N., et al. Depression and bone mineral density in a community sample of perimenopausal women: Geelong Osteoporosis Study. Menopause 12 1 (2005) 88-91
37. Eskandari F., et al. Low bone mass in premenopausal women with depression. Arch. Intern. Med. 167 21 (2007) 2329-2336
38. Whooley M.A., et al. Depressive symptoms and bone mineral density in older men. J. Geriatr. Psychiatry Neurol. 17 2 (2004) 88-92
39. Whooley M.A., et al. Depression, falls, and risk of fracture in older women. Arch. Intern. Med. 159 (1999) 484-490
40. Sogaard A.J., et al. Long-term mental distress, bone mineral density and non-vertebral fractures. The Tromso Study. Osteoporos. Int. 16 8 (2005) 887-897
41. Reginster J.Y., et al. Depressive vulnerability is not an independent risk factor for osteoporosis in postmenopausal women. Maturitas 33 (1999) 133-137
42. Whitson H.E., et al. Depressive symptomatology and fracture risk in community-dwelling older men and women. Aging Clin. Exp. Res. 20 (2008) 585-592
43. Mezuk B., Eaton W.W., and Golden S.H. Depression and osteoporosis: epidemiology and potential mediating pathways. Osteoporos. Int. 19 1 (2008) 1-12
44. Kerse N., et al. Falls, depression, and antidepressants in later life: a large primary care appraisal. Plos ONE 3 6 (2008) e2423
45. Thapa P.B., et al. Antidepressants and the risk of falls among nursing home residents. N. Engl. J. Med. 339 13 (1998) 875-882
46. Ensrud K.E., et al. Central nervous system-active medications and risk for falls in older women. J. Am. Geriatr. Soc. 50 (2002) 1629-1637
47. Tolea M.I., et al. Depressive symptoms as a risk factor for osteoporosis and fractures in older Mexican American women. Osteoporos. Int. 18 (2007) 315-322
48. Forsen L., et al. Mental distress and risk of hip fracture. Do broken hearts lead to broken bones?. J. Epidemiol. Commun. Health 53 (1999) 343-347
49. Williams L.J., et al. Depression and bone metabolism. Psychother. Psychosom. 78 (2009) 16-25
50. Haney E.M., and Warden S.J. Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from clinical studies. J. Musculoskelet. Neuronal Interact. 8 2 (2008) 133-145
51. Sterke C.S., et al. The influence of drug use on fall incidents among nursing home residents: a systematic review. International Psychogeriatrics 20 05 (2008) 890-910 doi:10.1017/S104161020800714X
52. Hartikainen S., Lonnroos E., and Louhivuori K. Medication as a risk factor for falls: critical systematic review. J. Gerontol.: Med. Sci. 62A 10 (2007) 1172-1181
53. French D.D., et al. Drugs and falls in community-dwelling older people: a national veterans study. Clin. Ther. 28 4 (2006) 619-630
54. Landi F., et al. Psychotropic medications and risk for falls among community-dwelling frail older people: an observational study. J. Gerontol. A. Biol. Sci. Med. Sci. 60 5 (2005) 622-626
55. Canalis E., et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 18 (2007) 1319-1328
56. Canalis E., et al. Perspectives on glucocorticoid-induced osteoporosis. Bone 34 4 (2004) 593-598
57. National Osteoporosis Foundation, Clinician's Guide to Prevention and Treatment of Osteoporosis. 2008: Washington, DC.
58. Yu E.W., et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif. Tissue Int. 83 (2008) 251-259
59. Yang Y.Z., et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296 24 (2006) 2947-2953
60. Targownik L.E., et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ: Can. Med. Assoc. J. 179 4 (2008) 319-326
61. Richards J.B., and Goltzman D. Proton pump inhibitors: balancing the benefits and potential fracture risks. CMAJ: Can. Med. Assoc. J. 179 4 (2008) 306-307
62. Vestergaard P. Bone metabolism in type 2 diabetes and role of thiazolidinediones. Curr. Opin. Endocrinol. Diabetes Obes. 16 (2009) 125-131
63. Solomon D.H., et al. A cohort study of thiazolidinediones and fractures in older adults with diabetes. 10.1210/jc.2008-2157. J. Clin. Endocrinol. Metab. (2009) jc.2008-2157
64. Lipscombe L.L. Thiazolidinediones: do harms outweigh benefits?. CMAJ: Can. Med. Assoc. J. 180 1 (2009) 16-17
65. Harris R.P., et al. Current methods of the U.S. Preventive Services Task Force: a review of the process. Am. J. Prev. Med. 3 suppl 1 (2001) 21-35
66. U.S. Preventive Services Task Force, Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann. Intern. Med. 137 6 (2002) 526-528
67. Weintrob N., et al. Decreased growth during therapy with selective serotonin reuptake inhibitors. 10.1001/archpedi.156.7.696. Arch. Pediatr. Adolesc. Med. 156 7 (2002) 696-701